Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Aim: The aim of this study is to evaluate the occurrence and nature of space occupying lesions (SOL) on liver imaging in
patients with chronic hepatitis C (CHC) receiving antiviral therapy (AVT).
Methods: 1540 patients (from January 2002 to July 2014) with CHC who underwent ultrasound (USG) scan, liver biopsy (LB)
and received conventional (pegylated interferon and ribavirin) dual AVT were retrospectively analyzed for the occurrence and
nature of SOL prior to initiation of AVT and thereafter.
Results: Mean age of patients were 41.9±9.7 years (85% males), predominantly genotype 4 (65%) and genotype 1 (11%).
Pretreatment LB showed (Scheuer classification) stage-0 fibrosis (F0) in 1.9%, stage-1 (F1) in 32.9%, stage-2 (F2) in 39.5%, stage-3
(F3) in 19% and stage-4 (F4) in 6.6% patients. Median follow-up was 3.5 years (5390 patient years). Computed Tomography
(CT) and Magnetic resonance imaging (MR) scans were performed in 1185 and 560 patients respectively prior to AVT and
during follow up. Of the patients with F4 on LB, USG identified cirrhosis in 68%. Of all the patients reported with cirrhosis
on USG, F4 was seen in 16.6% and advanced fibrosis (F3 and F4) in 53.4%. Routine pretreatment USG showed fatty liver in
334 (20.8%). Incidental SOL included, cysts in 21 (1.3%), hemangioma in 41 (2.6%) and hypoechoic lesions in 14 (0.9%). CT
and/or MR scan did not change diagnosis in most of these SOL, except in two hypoechoic lesions detected pretreatment (one
was confirmed as hepatocellular carcinoma (HCC) by CT and another by MR) and one hypoechoic lesion during post AVT
follow up (confirmed as HCC in MR). CT and MR identified three and one HCC respectively that were missed on USG against
cirrhotic background. Four patients had HCC during pretreatment evaluation and 11 developed new onset HCC during post
AVT follow up. The mean alpha fetoprotein (AFP) at diagnosis of new onset HCC was 63.3±1173.8 (vs 16.2±118.1 for non
HCC patients, p=0.001). Elevated AFP levels were seen in 81.8% of these patients. Independent pretreatment predictors of new
onset HCC were pre-AVT albumin and GGT.
Conclusions: Most of the incidental SOL detected in routine pre-AVT USG retained diagnostic consistency with further
radiological imaging with CT and MR. A predicting model including pre-AVT albumin and GGT showed high predictive
accuracy for development of HCC during post treatment follow up; which could be used as a guide to consider further
radiologic evaluation in these incidental SOL.